SGLT2阻害剤とクルクミンを併用したリポソーマ製剤は,心不全の治療のためのシナージスティックな投与システムである
Bianca-Ștefania Profire1, Florentina Geanina Lupașcu2, Alexandru Sava2
1Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy of Iasi, 16 University Street, 700115 Iași, Romania.
Pharmaceutics
|August 28, 2025
まとめ
この研究では,SGLT2阻害剤 (ダパグリフロジンおよびエンパグリフロジン) とクルクミンを併用して心臓不全の治療を行う新しいリポソーマル投与システムを開発した. 最適化された製剤は持続的な薬剤の放出と安定性を示し,標的型心不全治療の有望性を示した.
科学分野:
- 医薬品科学
- 薬物投与システム
- ナノテクノロジー
背景:
- 心不全 (HF) は治療上の大きな課題です.
- 効率的なHF管理には新しいシナジスティック戦略が必要である.
- リポソーム共配システムは,治療の成果を向上させる可能性を秘めています.
研究 の 目的:
- SGLT2阻害剤 (ダパグリフロジン-DAPA,エムパグリフロジン-EMPA) とカーキュミン (Cur) を併用したリポソーマ系を心不全 (HF) の治療に用いる.
- オレアノール酸 (OA) とポリビニルピロリドン (PVP) のコーティングを使用して,リポソーマの安定性を高め,持続的な薬剤の放出を達成します.
- 開発されたリポソーマル製剤の物理化学的性質とインビトロ性能を評価する.
主な方法:
- DAPA,EMPA,Curを併封したリポソーマ製剤.
- オレアノール酸 (OA) を脂質二層に組み込んで安定させる.
- リポソームの表面をポリビニルピロリドン (PVP) でコーティングする.
- 粒子の大きさ分析,ゼータポテンシャル,STEM,XRD,DSC,およびin vitro放出試験を用いた特徴付け.
主要な成果:
- リポソームは最適な粒径 (~170 nm),低PDI,負のゼータポテンシャルを示した.
- 高い封装効率 (97%まで) と球状の形状が達成されました.
- XRDとDSCは成功裏に APIの組み込みと無形化を確認した.
- PVPコーティングは熱安定性を改善し,トリハロースは効果的な冷凍剤として作用しました.
- In vitro試験では,特にOAを含むおよびPVPコーティングされた製剤では,薬剤の持続的および遅れた放出が示されました.
結論:
- SGLT2阻害剤とクルクミンを併用したPVPコーティングされたOA安定化リポソームは,有望な生物互換性プラットフォームを表しています.
- これらの多機能リポソームは,標的型心不全治療に適しています.
- 開発されたシステムは,心不全の合同的な治療のための新しいアプローチを提供します.
さらに関連する動画
05:55Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
Published on: September 18, 2018
8.8K
05:08Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
Published on: September 20, 2017
17.0K
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:27Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27